Description
Immunomax Pharmacodynamics
Immunomax enhances immune defense against viral and bacterial infections. Immunopharmacological mechanisms of action of the drug is that Immunomax activates the following parts of the immune system:
– NK-cells, which, after 2-3 hours, after exposure to Immunomax, intensely expresses CD69 activation molecules. Cytolytic activity of NK-cells increases 3-fold;
– Circulating monocytes 2-4 hours after Immunomax activation start secreting cytokines: interleukin-8, interleukin-1? and tumor necrosis factor alpha;
– neutrophil granulocytes are activated through monocytes, the drug has no direct effect on neutrophil granulocytes. Interleukin-8 secreted by monocytes causes activation of neutrophil granulocytes, which is clearly evident 24 hours after exposure to Immunomax;
– tissue macrophages, which is manifested by changes in the morphology of these cells, increased production of bactericidal substances, changes in the activity of 5′-nucleotidase;
– formation of antibodies against foreign antigens, soluble and corpuscular;
Immunomax enhances protection against infections caused by viruses (human papillomavirus, herpes simplex virus, parvovirus, plague virus, etc.) or bacteria (E. coli, salmonella, staphylococcus, chlamydia, mycoplasma, ureaplasma, etc.). This effect of the drug is manifested in adults and newborns when administering Immunomax in different ways: intramuscularly, intravenously, intraperitoneally, reg os.
Indications
-Correction of weakened immunity;
– Treatment of pathological conditions (condylomas, warts, dysplasia, etc.) caused by human papilloma virus;
– Treatment of infections caused by herpes simplex virus, chlamydia, mycoplasma, ureaplasma, other bacteria and viruses.
Contraindications
Individual hypersensitivity to Immunomax. Childhood under 12 years of age.
With caution:
There are no specifics for the use of the drug by children and adults with chronic diseases.
Pregnancy and lactation:
Use is possible only if the potential benefit to the pregnant woman exceeds the possible harm to the fetus. Immunomax is not recommended for use in lactating mothers.
Dosage and administration
- Before use, the drug is dissolved in 1 ml of water for injection.
- The recommended dose for adults and children 12 years of age and older is 100-200/ED, depending on the disease severity. The drug is administered intramuscularly, once a day. The course of treatment is 6 injections on days 1, 2, 3, 8, 9, 10 of treatment.
- For the treatment of recurrent anogenital warts, the course of 6 injections of 200 IU of Immunomax is combined with the destruction of the warts by one of the standard methods: cryoablation, electrocoagulation, laser destruction or solcoderm.
- For the treatment of infections caused by bacteria or viruses, a course of 6 injections of 100-200 IU of Immunomax is performed.
- For the correction of weakened immunity, a course of 3-6 injections of 100-200 IU of Immunomax is carried out.
